MBXBF Stock UPDATES Microbix Biosystems (MBXBF) 0.4720 08/20/2014
Post# of 273334
Posted On: 08/20/2014 8:37:32 AM
Microbix Biosystems (MBXBF) 0.4720 $MBXBF
eResearch Posts Update Report on Microbix Biosystems Inc.
ACCESSWIRE - Wed Feb 26, 1:52PM CST
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.
eResearch Posts Perspective on Microbix Biosystems Inc.
ACCESSWIRE - Mon Jan 27, 6:27AM CST
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.
IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - Microbix Biosystems Inc., MBX
Marketwire Canada - Thu Jan 23, 11:49AM CST
Trading resumes in / Reprise des negociations pour :
IIROC Trade Resumption - Microbix Biosystems Inc.
Newsfile Corp - Thu Jan 23, 10:57AM CST
Trading resumes in:
Competitor Analysis: Thrombolytics & Fibrinolytics
M2 - Mon May 20, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j3c6qc/competitor) has announced the addition of the "Competitor Analysis: Thrombolytics & Fibrinolytics" report to their offering. The Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report provides information on the various generation of marketed thrombolytics and includes a compilation of current active projects in research and development of novel thrombolytics and fibrinolytics including those in development in ophthalmology and in less regulated markets. In addition, the report lists company-specific product portfolios and R&D pipelines of thrombolytics and fibrinolytics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Examples of Companies Mentioned - Actavis - Alcon - Astellas Pharma - Bharat Biotech - Biocon - BioGeneric Pharma - Cadila Pharma - Cerbios Pharma - Cerevast Therapeutics - CSL Behring - Dexa Medica - Eisai - Ekos Corp - Grifols - Heber Biotec - Kedrion - Kee Pharma - Lundbeck - Microbix Biosystems - Mitsubishi Tanabe Pharma - Nanogen Biopharmaceuticals - ProteomTech - Pulse Therapeutics - Roche (Genentech) - Shantha Biotechnics (Sanofi) - Techpool BioPharma - Thrombogenics - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/j3c6qc/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Microbix reports fiscal 2013 first quarter results
CNW Group - Thu Feb 14, 6:30AM CST
Company Provides Update on Product Pipeline
Microbix Sells Purified Water Business
CNW Group - Fri Feb 01, 6:30AM CST
Microbix Biosystems Inc. (TSX: MBX), a biotechnology company developing innovative biological products and technologies, today announced it has sold its Water-for-Injection business to Irvine Scientific in California. The sale was constructed on an earn-out basis, though specific deal terms were not disclosed.
Microbix' LumiSort Patent Upheld in U.S.
CNW Group - Fri Jan 25, 6:25AM CST
Sexing Technologies fails in second attempt to invalidate claims
Microbix Refiles Financial Statements
CNW Group - Thu Jan 10, 4:41PM CST
Microbix Biosystems Inc. (TSX:MBX) today refiled its financial statements for the year ended September 30, 2012 to correct two oversights in the Consolidated Statements of Comprehensive Loss.
Microbix Reports 15% Increase In Virology Product Sales In 2012
CNW Group - Fri Dec 28, 10:33PM CST
Urokinase, Vaccine Venture, and LumiSort Update
eResearch Posts Update Report on Microbix Biosystems Inc.
ACCESSWIRE - Wed Feb 26, 1:52PM CST
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.
eResearch Posts Perspective on Microbix Biosystems Inc.
ACCESSWIRE - Mon Jan 27, 6:27AM CST
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.
IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - Microbix Biosystems Inc., MBX
Marketwire Canada - Thu Jan 23, 11:49AM CST
Trading resumes in / Reprise des negociations pour :
IIROC Trade Resumption - Microbix Biosystems Inc.
Newsfile Corp - Thu Jan 23, 10:57AM CST
Trading resumes in:
Competitor Analysis: Thrombolytics & Fibrinolytics
M2 - Mon May 20, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j3c6qc/competitor) has announced the addition of the "Competitor Analysis: Thrombolytics & Fibrinolytics" report to their offering. The Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report provides information on the various generation of marketed thrombolytics and includes a compilation of current active projects in research and development of novel thrombolytics and fibrinolytics including those in development in ophthalmology and in less regulated markets. In addition, the report lists company-specific product portfolios and R&D pipelines of thrombolytics and fibrinolytics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Examples of Companies Mentioned - Actavis - Alcon - Astellas Pharma - Bharat Biotech - Biocon - BioGeneric Pharma - Cadila Pharma - Cerbios Pharma - Cerevast Therapeutics - CSL Behring - Dexa Medica - Eisai - Ekos Corp - Grifols - Heber Biotec - Kedrion - Kee Pharma - Lundbeck - Microbix Biosystems - Mitsubishi Tanabe Pharma - Nanogen Biopharmaceuticals - ProteomTech - Pulse Therapeutics - Roche (Genentech) - Shantha Biotechnics (Sanofi) - Techpool BioPharma - Thrombogenics - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/j3c6qc/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Microbix reports fiscal 2013 first quarter results
CNW Group - Thu Feb 14, 6:30AM CST
Company Provides Update on Product Pipeline
Microbix Sells Purified Water Business
CNW Group - Fri Feb 01, 6:30AM CST
Microbix Biosystems Inc. (TSX: MBX), a biotechnology company developing innovative biological products and technologies, today announced it has sold its Water-for-Injection business to Irvine Scientific in California. The sale was constructed on an earn-out basis, though specific deal terms were not disclosed.
Microbix' LumiSort Patent Upheld in U.S.
CNW Group - Fri Jan 25, 6:25AM CST
Sexing Technologies fails in second attempt to invalidate claims
Microbix Refiles Financial Statements
CNW Group - Thu Jan 10, 4:41PM CST
Microbix Biosystems Inc. (TSX:MBX) today refiled its financial statements for the year ended September 30, 2012 to correct two oversights in the Consolidated Statements of Comprehensive Loss.
Microbix Reports 15% Increase In Virology Product Sales In 2012
CNW Group - Fri Dec 28, 10:33PM CST
Urokinase, Vaccine Venture, and LumiSort Update
(0)
(0)